
-
Altimmune Inc. NasdaqGM:ALT Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Location: 910 Clopper Road, Gaithersburg, MD, 20878, United States | Website: https://altimmune.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
292.2M
Cash
149.8M
Avg Qtr Burn
-20.08M
Short % of Float
28.19%
Insider Ownership
0.76%
Institutional Own.
47.87%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Pemvidutide (ALT-801) (GLP-1R/GCGR) Details metabolic dysfunction-associated steatohepatitis (MASH) Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 2b Data readout | |
Pemvidutide (ALT-801) (GLP-1R/GCGR) Details Non-alcoholic steatohepatitis , Non-Alcoholic Fatty Liver Disease, metabolic dysfunction-associated steatohepatitis | Phase 2b Data readout | |
Pemvidutide (ALT-801) (GLP-1R/GCGR) Details Alcohol Use Disorder | Phase 2 Data readout | |
Phase 2 Update | ||
Pemvidutide (ALT-801) (GLP-1R/GCGR) Details Type 2 diabetes | Phase 2 Initiation | |
Pemvidutide (ALT-801) (GLP-1R/GCGR) Details Alcohol-Associated Liver Disease | Phase 2 Initiation | |
NasoShield (Vaccine) Details Anthrax, Bacterial infection | Failed Discontinued | |
HepTCell Details Chronic hepatitis B | Failed Discontinued | |
NasoVAX Details Influenza | Failed Discontinued | |
AdCOVID Details COVID-19 | Failed Discontinued | |
T-COVID Details COVID-19 | Failed Discontinued |